Future Pharmacology · 2023 · 48 citations · 79 references
Life SciencesNeurosciencePharmacologyDementiaNeurodegenerationNeuropharmacologyAlzheimer DiseaseMedicinal PlantsNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease NeuroprotectionAlzheimer Disease ProgressionBioactive Plant CompoundsNeuroprotective AgentsNeuroprotective MechanismsNeuroprotective Natural ProductsPlant-based TherapeuticsPlant-derived Natural Products
Alzheimer’s disease (AD) is a progressive, multifactorial, and unremitting neurodegenerative disease characterized by memory loss, personality changes, and cognitive impairment. It has become more prevalent in recent years. Therefore, understanding the pathophysiology of AD and developing efficient therapeutic strategies are essential. Moreover, the progression of the disease is unaffected by the pharmaceutical approaches discovered to date. Additionally, the failure of over 200 potential drug candidates in clinical trials over the past decade suggests the complexity and difficulty of both the disease and its underlying causes. Therefore, research focused on medicinal plant-based natural products in the search for novel neuroprotective therapeutic candidates for AD is essential. Indeed, several scientific investigations have demonstrated the efficacy of many medicinal plants and their principal phytochemicals in the treatment of AD. This review article covered the pathophysiological mechanisms of AD, the necessity for natural products as anti-AD treatments, and the most recent preclinical studies revealing the function of neuroprotective medicinal plants and their bioactive compounds in the effective management of AD. In addition, the review also presents clinical trial data of promising anti-AD formulations/agents of plant origin. Revealing recent findings and highlighting the clinical trial data related to the development of new treatments for AD would promote further research in this field and pave the way for the development of more effective and safe treatments for this debilitating disease.
79
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Willemijn J. Jansen, Olin Janssen, Betty M. Tijms et al. · JAMA Neurology · 2022 · 288 citations · Full text
Medicine, Neurology, Neuroscience +17
PICALM modulates autophagy activity and tau accumulation
Kévin Moreau, Angeleen Fleming, Sara Imarisio et al. · Nature Communications · 2014 · 277 citations · Full text